Mode
Text Size
Log in / Sign up

Preoperative chemoradiotherapy increases R0 resection and pathologic complete response rates in esophageal carcinomaRadiotherapy Combined with Chemotherapy Shows Better Local Control for Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that chemoradiotherapy improves R0 resection and pathological response but does not significantly improve survival.

This meta-analysis of randomized controlled trials evaluated the efficacy of perioperative chemotherapy compared to preoperative chemoradiotherapy for patients with resectable esophageal or gastroesophageal junction carcinoma. The analysis focused on local control markers, including R0 resection rates and pathologic complete response.

The synthesis indicates that preoperative chemoradiotherapy is associated with significantly higher R0 resection rates (RR 0.94; 95% CI 0.89, 0.99) and higher pathologic complete response rates (RR 0.27; 95% CI 0.13, 0.58) compared to perioperative chemotherapy. Despite these improvements in local control metrics, the meta-analysis found no statistically significant differences between the two regimens regarding overall survival, progression-free survival, postoperative mortality, or severe adverse events.

A noted limitation is that tests for subgroup differences specifically in squamous cell carcinoma did not reach statistical significance. While chemoradiotherapy improves local tumor control indicators, it does not currently demonstrate a clear survival advantage over chemotherapy in this population. Clinical application should consider these findings when balancing local control goals against the lack of demonstrated survival benefit.

How this fits prior evidence

This meta-analysis addresses the management of resectable esophageal carcinoma by comparing chemoradiotherapy to perioperative chemotherapy. It complements existing evidence regarding SIB-RT plus S-1 for elderly inoperable cases by providing data on the local control benefits of chemoradiotherapy in resectable cases, specifically showing higher R0 resection rates (RR 0.94) and pathologic complete response (RR 0.27).

Researchers analyzed data from multiple clinical trials to compare two different treatment paths for adults with resectable esophageal or gastroesophageal junction carcinoma. The study compared perioperative chemotherapy (CT) against preoperative chemoradiotherapy (CRT), which includes both chemotherapy and radiation before surgery.

The results showed that patients who received the combination of chemotherapy and radiation had significantly higher rates of complete response and R0 resection, which means the surgical removal of the tumor. While the combined treatment improved these local markers, there was no statistically significant difference between the two methods regarding overall survival or progression-free survival.

Safety data did not show a significant difference in severe adverse events between the two groups. Because this is a meta-analysis of existing trials, it provides a broad look at current options but does not replace individual clinical judgment. Patients should discuss these specific outcomes with their oncology team to determine the best approach for their unique situation.

What this means for you:
Adding radiation to chemotherapy before surgery may improve tumor removal rates but did not change overall survival.

Common questions

How does adding radiation to chemotherapy affect surgical outcomes?

Adding radiation to chemotherapy (CRT) showed significantly higher rates of pathologic complete response and R0 resection compared to using only chemotherapy (CT). This means the combination treatment was more effective at clearing the tumor locally before surgery.

Does the combination of radiation and chemotherapy help patients live longer?

The study found no statistically significant difference in overall survival or progression-free survival between those who received only chemotherapy and those who received both chemotherapy and radiation. Both groups showed similar results regarding how long patients lived after treatment.

Are there more side effects with the combined treatment?

The study found no statistically significant difference in severe adverse events between the two treatment methods. Patients receiving both chemotherapy and radiation did not experience a higher rate of serious complications compared to those receiving only chemotherapy.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up216.0 mo
PublishedJun 2026
View Original Abstract ↓
BACKGROUND: The optimal approach between perioperative chemotherapy (CT) versus preoperative chemoradiotherapy (CRT) for esophageal carcinoma remains debated. This meta-analysis compares the safety and efficacy of CT versus CRT in resectable esophageal and gastroesophageal junction carcinoma. METHODS: Electronic databases were systematically searched for eligible randomized controlled trials (RCTs) that enrolled adult patients (aged ≥ 18 years) with histologically confirmed, resectable esophageal or gastroesophageal junction carcinoma, directly compared perioperative CT with preoperative CRT, and reported at least one outcome of interest. Meta-analysis was conducted using RevMan 5.4 with a random-effects model. Hazard Ratios (HRs) were pooled for time-to-event outcomes, and risk ratios (RR) for dichotomous endpoints. RESULTS: Eight RCTs were included. Compared with CRT, CT had significantly reduced R0 resection rates (RR 0.94, 95% CI 0.89, 0.99) and a lower pathologic complete response (RR 0.27, 95% CI 0.13, 0.58). No statistically significant differences were observed in overall survival, progression-free survival, postoperative mortality, or severe adverse events. There was a trend toward greater benefit of CRT in squamous cell carcinoma; however, the test for subgroup differences did not attain statistical significance. CONCLUSION: This meta-analysis suggests that CRT improves local tumor control by increasing R0 resection rates and complete response rates, but without a clear survival advantage over CT. This meta-analysis further highlights the need for an updated multidisciplinary framework and highlights the importance of biomarker-driven strategies in future research.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.